Tiziana Life Sciences to Participate in 2022 Biotech Showcase Virtual Investor Conference

Rhea-AI Summary

Tiziana Life Sciences (Nasdaq: TLSA) announced participation at the virtual Biotech Showcase Conference on January 10-12 and 17-19, 2022. Senior management will present and be available for one-on-one meetings throughout the event. Tiziana focuses on innovative drug delivery methods, including nasal, oral, and inhalation routes, to enhance immunotherapy efficacy and safety. Their lead candidates include intranasal foralumab and milciclib, both showing promising clinical results. For more details about the conference, registration is available online.

NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) (“Tiziana”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announced that senior management will present at the Biotech Showcase Conference and be available for one-on-one meetings throughout the conference. The conference is being held virtually from January 10^th -12^th and also during January 17^th -19^th.  

Conference details can be found below:

Biotech Showcase

Date:		January 10-12 and 17-19, 2022
Format:		On-demand presentation (available January 7, 2022) and one-on-meetings
Registration:		Click here

About Tiziana Life Sciences

Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s two lead candidates, intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For further information please contact:

Hana Malik, Business Development and Investor Relations Manager  
+44 (0) 207 495 2379
email: info@tizianalifesciences.com

United States:

Investors:
Irina Koffler
LifeSci Advisors
Tel: (646) 970-4681
ikoffler@lifesciadvisors.com

FAQ

When is the Biotech Showcase Conference where TLSA will present?

The Biotech Showcase Conference will be held virtually on January 10-12 and January 17-19, 2022.

What is Tiziana Life Sciences' focus in biotechnology?

Tiziana Life Sciences focuses on breakthrough therapies using novel routes of drug delivery for immunotherapy.

What are the lead candidates of TLSA mentioned in the press release?

The lead candidates are intranasal foralumab and milciclib, both showing favorable safety profiles.

How can I register for the Biotech Showcase Conference?

You can register for the Biotech Showcase Conference through the official website linked in the press release.

What innovative approaches does TLSA develop for drug delivery?

TLSA develops nasal, oral, and inhalation approaches to improve the efficacy and safety of immunotherapy.